Global Top Players in Intraocular Lens (IOL) Market
Global Top Players in Intraocular Lens (IOL) Market
New Frontiers in Uveitis Treatment: Updates and Innovations  
Analyzing the Most Promising Drugs That Will Lose Patent in the U...
von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!
Prominent Players in Glaucoma Drainage Devices Market

Search by Categories

Home / Blog / Ophthalmology / 4

Ophthalmology

Bausch + Lomb and Heidelberg Engineering Introd...

Bausch + Lomb and Heidelberg Engineering Introduced SeeLuma™ Fully Digital Surgical Visualization Platform  On April 13, 2023, Bausch + Lomb, a leading global eye health company dedicat...

Apr 20, 2023

MedTech News for Bausch + Lomb, Heidelberg Engineering, Oxford Nanopore, bioMérieux, Senseonics, Boomerang Medical, RapidAI, Neuspera Medical
Pharma News and Updates for RegeneRx, Aldeyra, Oncolyze, Soligenix, Aviceda
RegeneRx’s Phase 3 Neurotrophic Keratitis Clinical Trial of RGN-259; Aldeyra’s Phase 3 INVIGORATE-2 Clinical Trial Update; FDA Orphan Drug Designation to Oncolyze’s OM-301 for Multiple Myeloma; Soligenix Provides Regulatory Update on HyBryte; FDA Fast Track Designation to SAB Biotherapeutics’s SAB-176 Influenza Immunotherapy; Aviceda IND Application for AVD-104

RegeneRx Biopharmaceuticals Enrolled First Patient in the Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259 in the US On April 12, 2023, RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company") announced that the first patient of Phase 3 clinical trial (SEER-2) of RGN-259, a novel treat...

Find More
Pharma News and updates for HUTCHMED, Cytokinetics, Astellas, Seagen, Nanoscope Therapeutics, Cabaletta Bio, Decibel Therapeutics
HUTCHMED’s NDA Submission to FDA for Fruquintinib; Cytokinetics to Discontinue ALS Drug Candidate Following Phase III Trial Failure; Enfortumab Vedotin + Pembrolizumab Approved for Urothelial Carcinoma; Nanoscope Gene Therapy Clears Phase II Retinitis Pigmentosa Trial; FDA Clearance to Cabaletta Bio’s IND Application for CABA-201 for SLE Treatment; European Orphan Drug Designation to Gene Therapy Candidate DB-OTO

HUTCHMED Completes Rolling Submission of NDA to FDA for Fruquintinib HUTCHMED (China) Limited announced the completion of the rolling submission of a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") for fruquintinib, its highly selective and potent oral inhibitor of VEGFR-1,...

Find More
MedTech News and Update for Sight Sciences, HeartBeam, LIVMOR, Occlutech, PADM Medical, Kardium, LivaNova
Sight Sciences’s Ergo-Series of the OMNI® Surgical System; HeartBeam to Acquire LIVMOR’s Assets; Occlutech Atrial Flow Regulator (FROST-HF) Study Updates; US FDA 510(k) Clearance for PADM Medical’s PRECISION ECO; Kardium ‘s Pulsed-Field Ablation Study; US FDA 510(k) Clearance for LivaNova’s Essenz Heart-Lung Machine

Ergo-Series of the OMNI® Surgical System Launched by Sight Sciences On March 9, 2023, Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative technology, providing solutions for transforming care and improving patients' lives, announced the launch of the Ergo-Seri...

Find More

More Views & Analysis

Pharma News and Updates for Actinium, Apellis, Chiesi, IVERIC, Travere, Takeda
Actinium Announces Phase III SIERRA Trial Results; FDA Approves Apellis’s Geographic Atrophy Drug; FDA Gives Green Light to Chiesi’s Lamzede; FDA Accepts NDA and Grants Priority Review for Avacincaptad Pegol; FDA Approves Travere’s Kidney Disorder Drug; Takeda Presents Phase 3 GRAPHITE Study Results

Actinium Announces Positive Full Data Results From the Pivotal Phase III SIERRA Trial Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, announced positive primary and secondary endpoint results from its pivotal Phase III SIERRA trial of Iomab-B in patients aged 55 and older...

Find More
Pharma News and Updates for Leo Pharma, GSK, Roche, Aldeyra, IASO Bio
Leo Pharma’s Hand Eczema Clinical Trial Updates; GSK’s PD-1 inhibitor Jemperli Approval; Roche Announces Phase III Result of Vabysmo; FDA Accepts NDA for Aldeyra’s reproxalap; RMAT and Fast Track Designations to IASO Bio’s CT103A; Orphan Drug Designation to Jubilant Therapeutics’s JBI-778

Leo Pharma Announces Positive Results of Phase III Hand Eczema Clinical Trial LEO Pharma A/S, a global leader in medical dermatology, announced that the DELTA 2 trial yielded positive results. DELTA 2 is the second of two pivotal phase III clinical trials involving delgocitinib cream, an investigational topical ...

Find More
Pharma News Updates for Merck, Sanofi, GSK, Hinova, Endogena, Amylyx
Merck’s Keytruda Wins Another FDA Approval; Sanofi Pauses Trial of Myasthenia Gravis Drug, tolebrutinib; FDA Approves GlaxoSmithKline’s Jesduvroq; FDA IND Application Clearance for Hinova’s HP518; FDA Fast Track Designation to Endogena’s EA-2353; Amylyx Updates on Global Phase 3 PHOENIX Trial

Merck Wins Another FDA Approval for Blockbuster Keytruda Merck & Co arrived just two months after GSK celebrated a positive phase III result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer. Keytruda (pembrolizumab) from Merck improved progression-free survival (PFS) vers...

Find More
Latest MedTech News and Updates for Tandem, NeuroMetrix, Cytovale, icotec ag
Tandem Acquires AMF Medical; NeuroMetrix Launched DPNCheck 2.0 Device; FDA Approves Cytovale’s IntelliSep Sepsis Test; FDA Clearance for the Ø 4.5mm VADER Pedicle Screws; Pie Medical Imaging’s vFFR FASTIII Trial; Hip Innovation Technology Announced Initiation Investigational Device Exemption Study

Tandem Diabetes Care Completed Acquisition of the Insulin Patch Pump Developer, AMF Medical On January 23, 2023, Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company, announced the complete acquisition of AMF Medical SA, the privately held Swiss developer of the SigiTM Patch Pump...

Find More
MedTech News for Cardiovascular Systems, Koneksa, Medcura, Abbott, Enovis, Bausch + Lomb, AcuFocus
First Patient Enrolled in Kaizen Clinical Study in Japan; Koneksa’s At-Home Mobile Spirometry Clinical Trial; Medcura’s LifeGel™ Absorbable Surgical Hemostat; FDA Clearance to Abbott’s NAVITOR; Enovis’s DynaClip Delta™ and DynaClip Quattro™ bone staples; Bausch + Lomb Acquired AcuFocus

First Patient Enrolled in Kaizen Clinical Study in Japan  On January 11, 2023, Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for patients suffering from peripheral and coronary artery disease, announced the initiation of the...

Find More
acute-ocular-pain-treatment-landscape
New Technologies Conquering Drug Delivery Obstacles in Acute Ocular Pain Treatment Landscape

Ocular pain is among the most common complaints in emergency clinics for medical attention. Most of the older population is affected by eye pain from post-ocular surgeries and debilitating eye conditions. Eye pain can be broadly classified as acute and chronic; eye pain exceeding 3 months is considered chronic. Mor...

Find More

Acromegaly is a rare, slowly progressive disorder that is caused when the pituitary glands produce t.....

Find More

Digital health technologies can fill the current gaps in oncology care while rebalancing the existin.....

Find More

Lupus Nephritis (LN) is one of the most common manifestations of systemic lupus erythematosus (SLE),.....

Find More

Today, the sedentary lifestyle adopted among people has led to cause a myriad of underlying diseases.....

Find More

Atrial fibrillation market is brimming with novel therapies in different stages of clinical developm.....

Find More

A complex genetic condition, Prader-Willi syndrome (PWS) is a result of the loss of the functioning .....

Find More